|Articles|June 3, 2009

Pharmaceutical Executive

  • Pharmaceutical Executive-06-03-2009
  • Volume 0
  • Issue 0

Elaine Eisen, CORBETT WORLDWIDE HEALTHCARE COMMUNICATIONS

Virtually all pharmaceutical manufacturers have robust policies to place needed medicines in the hands of those who cannot afford to pay for them.

Elaine Eisen

PRESIDENT | CORBETT WORLDWIDE HEALTHCARE COMMUNICATIONS

Ironically, pharma has many patient assistance programs already firmly in place (established well before the current economic downturn). There is probably no other industry in America that has as many established initiatives to assure continuity of care for the customer.

Virtually all pharmaceutical manufacturers have robust policies to place needed medicines in the hands of those who cannot afford to pay for them. Although this is certainly not an exhaustive list, what follows is merely a portion of the programs that pharma has sponsored to safeguard the health of patients: the AstraZeneca Prescription Savings Program, the Merck Patient Assistance Program, the Alcon U.S. Patient Assistance Program, the Pfizer Friends Program, the Bristol-Myers Squibb Patient Assistance Foundation, the Procter & Gamble Pharmaceuticals Patient Assistance Program, and the Sanofi-Aventis Patient Assistance Program. Perhaps pharma needs to "toot its own horn" a little more loudly and recognize that those of us who work in the pharmaceutical industry are dedicated to extending and enhancing human life.

Elaine Eisen

Articles in this issue

over 17 years ago

Frank X. Powers, DUDNYK

over 17 years ago

Didi Discar, MEDACCESS

over 17 years ago

Joe Daley, GSW WORLDWIDE

over 17 years ago

Jon Hudson, MEDTHINK COMMUNICATIONS

over 17 years ago

Wendy Blackburn, INTOUCH SOLUTIONS

over 17 years ago

Ross Fetterolf, IGNITE HEALTH

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.